Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of Infacort in neonates, infants, and children under 6 years with adrenal insufficiency
2014-002265-30Phase 3Completed
- Sponsor
- Diurnal Group plc
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone in hypoadrenocorticism and congenital adrenal hyperplasia (CAH), sponsored by Diurnal Group plc. Primary endpoint: Maximum serum cortisol concentration up to 240 minutes after dosing. Started Dec 2014; status: completed.
02
Drugs
hydrocortisone
03
Conditions
hypoadrenocorticismcongenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2014-002265-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002265-30.